TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7599666
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (1 and 2) after treatment
Study: 31177924
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg rectal)
Study: 21335941
Drug: Glycerin suppository
Normalized name: Leader Pediatric Glycerin Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerin suppository (placebo)
Study: 28947465
Drug: Continuous hyperosmolar
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous hyperosmolar therapy (20% NaCl) plus standard care
Study: 25032123
Drug: N‐acetyl‐cysteine (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N‐acetyl‐cysteine (NAC) (1200 mg/day)
Study: 25032123
Drug: Ginseng (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginseng (200 mg/day)
Study: 25032123
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antioxidant drugs)
Study: 23424164
Drug: Mirabegron 100
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron 100 mg BID
Study: 23424164
Drug: Mirabegron 150
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron 150 mg BID
Study: 23424164
Drug: Tolterodine 4
Normalized name: tolterodine 4 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 4 mg ER
Study: 19952809
Drug: Ibuprofen topical
Normalized name: ibuprofen topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen topical gel
Study: 18511165
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for 4 weeks
Study: 9201012
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention including in-hospital counseling, smoking cessation videotape, self-help literature, nicotine replacement therapy, and 3 months of telephone follow-up
Study: 8067229
Drug: Morphine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine + Ephedrine
Study: 5345935
Drug: Six-monthly chest
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six-monthly chest radiographs
Study: 31743406
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution eye drops
Study: 8706197
Drug: Edrophonium 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 1.0 mg x kg(‐1)
Study: 11512646
Drug: Edrophonium 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.4 mg x kg(‐1)
Study: 11512646
Drug: Edrophonium doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium doses (0.1, 0.2, 0.4, 1 mg x kg(‐1))
Study: 11512646
Drug: Cisatracurium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.1 mg x kg(‐1)
Study: 11512646
Drug: Edrophonium (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium (dose not specified)
Study: 8826506
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin cream applied 3 times daily for 5 weeks
Study: 8826506
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream applied 3 times daily for 5 weeks
Study: 3909798
Drug: Doxorubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60 mg/m2 I.V. day 1, observation after 500 mg/m2)
Study: 3909798
Drug: Doxorubicin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (40 mg/m2 I.V. day 1; maximum 500 mg/m2) and mitolactol (135 mg/m2 orally, days 1‐10; 180 mg/m2 after maximum doxorubicin)
Study: 24669876
Drug: Hydroxychloroquine 400
Normalized name: hydroxychloroquine 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 400 mg/day
Study: 22879929
Drug: Preemptive anidulafungin
Normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Preemptive anidulafungin treatment based on BDG surveillance
Study: 22879929
Drug: Empiric antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric antifungal treatment based on physician preference
Study: 11268714
Drug: Acarbose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (100 mg two to three times daily)
Study: 11268714
Drug: Gliclazide (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide (40-80 mg twice daily)
Study: 2404386
Drug: Method II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Method II: One catheter electrode and cutaneous patch (right ventricular cathode and cutaneous apical patch anode)
Study: 31383231
Drug: NightBalance sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: NightBalance sleep position treatment (SPT) device
Study: 28208806
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose OP beverage (77% OP)
Study: 28208806
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose OP beverage (35% OP)
Study: 28208806
Drug: Placebo (255
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (255 g)
Study: 25988560
Drug: pre‐S vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: pre‐S vaccine
Study: 23471586
Drug: Voluven 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voluven 5 ml/kg
Study: 23471586
Drug: Voluven 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voluven 7 ml/kg
Study: 23471586
Drug: Voluven 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voluven 9 ml/kg
Study: 15168020
Drug: 3.4 g
Normalized name: psyllium 3.4 g oral wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.4 g t10c12CLA for 12 weeks
Study: 11331320
Drug: 5‐FU 2,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU 2,600 mg/m2 by 24‐hour infusion, weekly
Study: 11331320
Drug: N‐phosphonoacetyl‐l‐aspartic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: N‐phosphonoacetyl‐l‐aspartic acid 250 mg/m2 day 1, 5‐FU 2,600 mg/m2 by 24‐hour infusion day 2, weekly
Study: 11331320
Drug: 5‐FU 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU 600 mg/m2 with oral leucovorin (LV) 125 mg/m2 hourly for the preceding 4 hours, weekly
Study: 11331320
Drug: 5‐FU 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU 600 mg/m2 with intravenous (IV) LV 600 mg/m2, weekly
Study: 11331320
Drug: 5‐FU 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU 750 mg/m2/d IV by continuous infusion for 5 days, then 750 mg/m2 weekly, and recombinant interferon alfa‐2a 9 million units subcutaneously three times weekly
Study: 11331320
Drug: 5‐FU as
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU as a 24‐hour infusion weekly (control group)
Study: 9223392
Drug: Pramlintide infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide infusion in insulin-treated patients
Study: 9223392
Drug: Pramlintide infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide infusion in diet/oral hypoglycaemic agents-treated patients
Study: 3555838
Drug: Nimodipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (40 mg three times daily)
Study: 3555838
Drug: Pizotifen (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pizotifen (0.5 mg three times daily)
Study: 28804048
Drug: Concurrent resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent resistance and aerobic exercise for 45 minutes
Study: 22435369
Drug: Tenecteplase (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenecteplase (0.1 mg/kg or 0.25 mg/kg)
Study: 18202419
Drug: CISCA/VB (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CISCA/VB (cyclophosphamide 400 mg/m(2) d1-2, doxorubicin 35 mg/m(2) d1-2, cisplatin 100 mg/m(2) d3/vinblastine 2.5 mg/m(2) d1-5)
Study: 18202419
Drug: BEP (bleomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEP (bleomycin 30 mg d1, d8, d15; etoposide 100 mg/m(2) d1-5; cisplatin 20 mg/m(2) d1-5)
Study: 8739864
Drug: H1-antagonist (terfenadine)
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H1-antagonist (terfenadine)
Study: 8739864
Drug: H2-antagonist (cimetidine)
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H2-antagonist (cimetidine)
Study: 8739864
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of H1 and H2 antagonists
Study: 1816109
Drug: Oral zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral zidovudine 250 mg twice daily combined with oral acyclovir 800 mg twice daily
Study: 1816109
Drug: Oral zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral zidovudine 250 mg twice daily combined with lymphoblastoid interferon‐alpha 1.5 x 10(6) IU administered subcutaneously three times weekly
Study: 6312008
Drug: Prednisone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (2 mg/kg/day)
Study: 25852045
Drug: Drug Education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Education in Victorian Schools program (intervention group, n=1,163)
Study: 25852045
Drug: Usual drug
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual drug education program (control group, n=589)
Study: 20676961
Drug: Standard HF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard HF treatment (n = 29)
Study: 357764
Drug: Furosemide, 40
Normalized name: Furosemide, 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide, 40 mg twice daily
Study: 357764
Drug: Hydrochlorothiazide, 50
Normalized name: HydroCHLOROthiazide, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide, 50 mg twice daily
Study: 22679249
Drug: Pitavastatin 1-4
Normalized name: pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin 1-4 mg
Study: 22679249
Drug: Pravastatin 10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10-40 mg
Study: 22679249
Drug: Pitavastatin low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pitavastatin low-dose (1 mg)
Study: 22679249
Drug: Pitavastatin intermediate-dose
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin intermediate-dose (2 mg)
Study: 22679249
Drug: Pitavastatin higher-dose
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin higher-dose (4 mg)
Study: 22679249
Drug: Pitavastatin low
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin low doses
Study: 22679249
Drug: Pravastatin low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin low doses
Study: 22679249
Drug: Pitavastatin intermediate
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin intermediate doses
Study: 22679249
Drug: Pravastatin intermediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin intermediate doses
Study: 22679249
Drug: Pitavastatin higher
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin higher doses
Study: 22679249
Drug: Pravastatin higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin higher doses
Study: 22051734
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (CT) based on clinical (C) and genomic (G) risk assessment
Study: 24618153
Drug: Anthracycline-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline-based chemotherapy
Study: 22051734
Drug: Docetaxel/capecitabine chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel/capecitabine chemotherapy
Study: 22051734
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy with letrozole
Study: 22051734
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy with tamoxifen→letrozole
Study: 19902755
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) combined with acupoint-injection (10 sessions of EA once a day for 10 days, and 5 sessions of acupoint-injection once every two days)
Study: 12570940
Drug: Intravenous glycoprotein
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glycoprotein IIb/IIIa receptor antagonists
Study: 12570940
Drug: Heparin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin infusion continued after the procedure
Study: 12570940
Drug: Heparin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin infusion discontinued after the procedure
Study: 3888734
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and insulin
Study: 29652462
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) for decontamination of implant surface
Study: 29652462
Drug: Chlorhexidine gel
Normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gel (CHX) followed by saline irrigation
Study: 24582046
Drug: Ivabradine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine 15 mg (single dose)
Study: 24582046
Drug: Ivabradine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine 10 mg (single dose)
Study: 24582046
Drug: Ivabradine 5
Normalized name: ivabradine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine 5 mg twice daily for 5 days
Study: 15727161
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (betahistine, Ginkgo biloba extract, dimenhydrinate)
Study: 11273927
Drug: Preemptive IA
Normalized name: magnesium aluminum silicate type Ia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive IA Morphine (3 mg)
Study: 11273927
Drug: Postoperative IA
Normalized name: magnesium aluminum silicate type Ia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative IA Morphine (3 mg)
Study: 8491304
Drug: Acetazolamide, 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide, 750 mg daily for 2 days before the ascent and on the first day at altitude (3,200 m)
Study: 3022035
Drug: Death due
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Death due to treatment
Study: 24213216
Drug: Once-weekly teriparatide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly teriparatide (56.5 μg for 72 weeks)
Study: 20554120
Drug: ANP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ANP infusion at the beginning of the 1st half of the night
Study: 20554120
Drug: ANP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ANP infusion at the beginning of the 2nd half of the night
Study: 16828095
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (25 mug every 6 hours)
Study: 12681024
Drug: Single-tablet metformin-glibenclamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-tablet metformin-glibenclamide combination therapy (Glucovance®)
Study: 12681024
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg and glibenclamide 2.5‐5 mg monotherapy
Study: 11015699
Drug: Numerical probability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Numerical probability presentation (e.g. 1:650 chance)
Study: 11015699
Drug: Verbal probability
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal probability presentation (e.g. 'your chance is low')
Study: 1452619
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of timolol (oral administration)
Study: 3867354
Drug: Cicletanine 300
Normalized name: cicletanine
DrugBank: Cicletanine (DB12766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 300 mg
Study: 31371810
Drug: Miso group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miso group (32 g 2:1 w/w Nenrin and MK‐34‐1 with 3.8 g salt/day)
Study: 31371810
Drug: Control soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control soy food group (14.4 g soy food with 0.2 g salt/day)
Study: 29431535
Drug: Differences in
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Differences in postprandial insulin between breakfasts
Study: 17511759
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZOL, 8 infusions at 4 mg during the first 12 months after LT), calcium (1000 mg/d), and vitamin D (800 IE/d)
Study: 17511759
Drug: Calcium (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1000 mg/d) and vitamin D (800 IE/d)
Study: 15660089
Drug: Pilocarpine (Salagen)
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine (Salagen) tablets, escalating doses of 2.5 mg to 5 mg or 5 mg to 7.5 mg qid for 6 weeks, followed by placebo qid for a 2-week washout period
Study: 10070908
Drug: Low-dose ramipril
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ramipril (1.25 mg orally once daily)
Study: 10070908
Drug: High-dose ramipril
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ramipril (10 mg orally once daily)
Study: 7585845
Drug: Cefodizime 1
Normalized name: cefodizime
DrugBank: Cefodizime (DB13470)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefodizime 1 g IM once daily (group A)
Study: 7585845
Drug: Cefodizime 1
Normalized name: cefodizime
DrugBank: Cefodizime (DB13470)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefodizime 1 g IM twice daily (group B)
Study: 7585845
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g IM once daily (group C)
Study: 29790804
Drug: Wartner (cryotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wartner (cryotherapy compound containing dimethyl ether 75% and propane 25%)
Study: 23410994
Drug: Lessons on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lessons on body size and eating enjoyment, and suggested weekly activities
Study: 19736898
Drug: Midazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (1 mg bolus followed by 1 mg h(‐1))
Study: 15030537
Drug: Dialysis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysis with acetate solution
Study: 15030537
Drug: Dialysis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysis with bicarbonate solution
Study: 21680997
Drug: Irbesartan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (150 mg titrated to 300 mg)
Study: 10687337
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate and dextromethorphan hydrobromide (MS:DM)
Study: 10687337
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate (MS) alone
Study: 29305456
Drug: Soap irrigation
Normalized name: Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soap irrigation solution
Study: 29305456
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline irrigation solution
Study: 26315303
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (220 mg zinc sulfate containing 50 mg zinc) for 8 weeks
Study: 24393852
Drug: Dinaciclib at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinaciclib at 50 mg/m², administered as a 2-hour infusion every 21 days
Study: 24393852
Drug: Capecitabine at
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine at 1250 mg/m², administered orally twice daily in 21-day cycles
Study: 17490968
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin A supplementation (60,000 microg to mothers and 7500 microg to infants)
Study: 17490968
Drug: Lower-dose vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose vitamin A supplementation (60,000 microg to mothers and 15,000 microg to infants)
Study: 10651974
Drug: rhDNase therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhDNase therapy (Pulmozyme(R)) over a 6-month period
Study: 8690562
Drug: rhDNase therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhDNase therapy
Study: 10651974
Drug: rhDNase therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhDNase therapy for subgroup of patients with moderate lung disease
Study: 10651974
Drug: rhDNase therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhDNase therapy for subgroup of patients
Study: 2147637
Drug: bezafibrate 400
Normalized name: bezafibrate 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate 400 mg day‐1
Study: 31258137
Drug: 1-day clear
Normalized name: clear days ahead
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day clear liquid diet (CLD) + polyethylene glycol and electrolyte lavage solution (PEG-ELS)
Study: 31258137
Drug: 3-day combined
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day combined diet (CMD) + polyethylene glycol and electrolyte lavage solution (PEG-ELS)
Study: 31258137
Drug: 1-day clear
Normalized name: clear days ahead
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day clear liquid diet (CLD) + sulfate free polyethylene glycol and electrolyte lavage solution (SF-PEG-ELS)